An open-label study assessing the safety and efficacy of naltrexone sustained release (SR)/bupropion sustained release (SR) in overweight or obese subjects with major depression.

Trial Profile

An open-label study assessing the safety and efficacy of naltrexone sustained release (SR)/bupropion sustained release (SR) in overweight or obese subjects with major depression.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Oct 2012

At a glance

  • Drugs Naltrexone/bupropion (Primary)
  • Indications Major depressive disorder; Obesity
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Dec 2010 Naltrexone/bupropion has received a positive recommendation from the FDA Advisory Committee for the treatment of obesity, as reported in an Orexigen Therapeutics and Takeda Pharmaceutical Company media release
    • 26 Jun 2010 Results presented at the 70th Annual Scientific Sessions of the American Diabetes Association, according to a Orexigen Therapeutics media release.
    • 26 Jun 2010 Primary endpoint 'Montgomery Asberg Depression Rating Scale' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top